---
search:
  boost: 2 
---

# Oral Acne Products

This is a subcategory of Dermatological Agents.

## Formulary

### Preferred

| Preferred       | Generic Name | Quantity | Time (Days) |
| :-------------- | :----------- | :------: | :---------: |
| Accutane <sup>PA</sup>     |              |          |             |
| Amnesteem <sup>PA</sup>     |              |          |             |
| Claravis <sup>PA</sup>      |              |          |             |
| Isotretinoin <sup>PA</sup>  |              |          |             |
| Myorisan <sup>PA</sup>      |              |          |             |
| Zenatane <sup>PA</sup>      |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Absorica      |              |          |             |
| Absorica LD   |              |          |             |

## Length of Authorizations

150 days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Clinical PA Criteria

- Must have had an inadequate clinical response of at least 90 days with at least **one preferred** topical **AND one preferred** oral antibiotic for acne
- Must be absent of oral tretinoin in the past 56 days
- Patient must be registered and meet all of the requirements of the iPLEDGE program

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **90 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Additional Information

- Authorization length will be for no more than 150 days at a time then must take 56
days off

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=49)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=19)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
